Washington produced a bumper crop of capital letters: GLOBE, GENIUS and a new official label for artificial intelligence. Apparently, a policy grows stronger when its acronym gets louder. The fine print decides who saves money, who gets access and who carries the risk.

Behind the branding are practical choices about Medicare drug bills, education expenses and the way people reach federal services. Acronyms may be mostly marketing, but that will not stop opinion and entertainment media from turning the substance of them into clickbait.

Teddy Brosevelt

What's Loud: The White House directed agencies to use “Super Intelligence” in place of “artificial intelligence.” The order changes the government's vocabulary for a familiar technology.

What's Missing: A separate order directs agencies to build America.gov as a unified entry point for federal services, with Login.gov handling identity verification. That quieter project could affect anyone applying for a benefit, checking a case or moving between agencies.

What Matters: A new label can spread through government quickly. A useful digital front door requires agencies to connect systems, protect personal data and remove dead ends. The service order will be harder to carry out and easier for the public to judge.

On October 2, the Centers for Medicare and Medicaid Services finalized a new way to calculate rebates on selected high-cost medicines administered in medical settings.

Under the Global Benchmark for Efficient Drug Pricing Model, or GLOBE, Medicare will compare its payments for selected Part B drugs with prices in 19 other countries. A manufacturer may owe a rebate when Medicare's payment exceeds the model's benchmark.

The model also lowers coinsurance for some Original Medicare patients in participating areas. On a $100 approved charge, a 10 percent GLOBE rate would leave the patient owing $10 instead of the usual $20. Medicare pays the provider's full approved amount and settles the manufacturer rebate later.

The program is not a direct price cap. It does not cover pharmacy drugs or Medicare Advantage members, and it will reach areas containing about one-quarter of Original Medicare beneficiaries.

CMS Administrator Dr. Mehmet Oz says patients and taxpayers should not pay far more than comparable countries for the same medicines. The Pharmaceutical Research and Manufacturers of America argues that the model could hurt access and medical research without reliably lowering patients' total costs.

The payment test begins April 1, 2027.

Our Deep Reason explainer separates the patient discount from the manufacturer rebate and examines the arguments for and against GLOBE.

Israel human-rights report. On September 29, the Senate voted 47–51 against a motion to consider Senate Resolution 852, which sought a State Department report on Israel's human-rights practices. The resolution would not have changed military aid by itself, but the report could have informed later decisions about United States security assistance.

School-choice tax credit. The Treasury Department and Internal Revenue Service proposed rules for the Education Freedom Tax Credit, the first nationwide federal school-choice program beginning in 2027. Donors can receive a credit for giving to approved scholarship organizations, which can help eligible families pay for private-school tuition, tutoring, special-needs services, books or computers. Parents will not receive a federal voucher check directly, and access will depend on whether their state participates and which expenses local scholarship organizations cover.

Trump Accounts. Treasury issued temporary rules for tax-advantaged investment accounts for children under 18 with Social Security numbers. Automatic enrollment can create an account, but families may still need to claim it and decide whether to contribute more money. During the growth period, withdrawals are restricted and investments are limited, so the account is designed for long-term saving rather than immediate family expenses.

Syria defense exports. The State Department removed Syria from the International Traffic in Arms Regulations policy of denial. Export-license requests involving Syria can be reviewed case by case, opening a path for some defense trade without granting blanket permission. Companies still need a license before any covered sale can proceed.

Pesticide competition. The Federal Trade Commission and state partners reached a proposed settlement with Corteva over an alleged scheme that paid distributors to limit purchases from generic pesticide makers after patents expired. The order would restrict those practices for 10 years, while litigation against Syngenta continues. More generic competition could reduce what farmers pay to protect crops, one cost that feeds into producing food.

Stablecoin safeguards. The Federal Reserve proposed capital, reserve, redemption and risk-management rules for stablecoin issuers it supervises under the GENIUS Act. The proposal seeks to ensure that a one-dollar token can be redeemed for one dollar and that its issuer has funds to absorb losses. The protections will matter most to people who use stablecoins for payments or hold them as cash-like assets.

$643.4 million in independent expenditures was reported to the Federal Election Commission during the first 18 months of the 2025–2026 election cycle.

What policy is creating a practical problem, or an unexpected benefit, where you live? Reply and tell us what the official announcement missed.